Skip to content
  • Tuesday, 29 September 2026
  • 11:28 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Enveda Biosciences Secures $311m in Series E Funding to Accelerate AI-Powered Natural Drug Discovery Pipeline
Pharmaceutical R&D

Enveda Biosciences Secures $311m in Series E Funding to Accelerate AI-Powered Natural Drug Discovery Pipeline

Teuku Ryan Sep 28, 2026 0

Colorado-based biotechnology pioneer Enveda Biosciences has officially closed a substantial $311m Series E financing round, bringing its cumulative venture backing…

Read More
Pharmaceutical R&D

Anixa Biosciences Secures Key Patent for Breast Cancer Vaccine Technology in South Korea, Expanding Global Intellectual Property Portfolio

Teuku Ryan Jul 1, 2026 0

Anixa Biosciences has achieved a significant milestone in its quest to develop a preventive vaccine for breast cancer, securing a…

Read More
Biotech & Genetic Research

INTEGRA Biosciences Automates Quantabio sparQ DNA Frag & Library Prep Kit Workflow, Enhancing NGS Efficiency and Reproducibility

Jia Lissa Jun 25, 2026 0

Zizers, Switzerland / Beverly, MA – INTEGRA Biosciences, a leading provider of high-quality laboratory tools for liquid handling and media…

Read More
Pharmaceutical R&D

Protuoso Biosciences Secures $9.5 Million Seed Funding to Pioneer Multifunctional Biologics for Complex Diseases

Teuku Ryan May 27, 2026 0

Protuoso Biosciences, a burgeoning US-based biotechnology company, has successfully closed a $9.5 million seed financing round, positioning itself to revolutionize…

Read More
Pharmaceutical R&D

Teva Pharmaceuticals Acquires Emalex Biosciences for $700 Million to Bolster Neurology Pipeline and Drive Growth Strategy

Teuku Ryan Apr 30, 2026 0

Teva Pharmaceuticals is set to significantly expand its presence in the neuroscience market with the acquisition of Emalex Biosciences, a…

Read More
Pharmaceutical R&D

Terremoto Biosciences Secures $108 Million Series C to Advance Next-Generation AKT1 Inhibitors for Oncology and Rare Diseases

Teuku Ryan Apr 16, 2026 0

Terremoto Biosciences, a pioneering biotechnology company at the forefront of developing novel therapeutics targeting the PI3K/AKT pathway, announced today the…

Read More
Europe Must Rethink Funding and De-Risk Assets to Secure its Rare Disease Research PipelineAI Can Accelerate Study-Build Foundations, But Only When Teams Combine Targeted Automation with Standards, Traceability and Control.TWiV 1288: Clinical update with Dr. Daniel GriffinInsilico CEO sees potentially $2.75 billion collaboration as ‘fusing Lilly’s clinical excellence’ with Insilico’s ‘end-to-end AI engine’
Japan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals PlummetMEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must Have
Dual-Drug Therapy Breakthrough Offers New Hope for Acute Myelogenous Leukemia Patients in Landmark Ludwig Cancer Research StudyMolten Salt Breakthrough: Oak Ridge Researchers Convert Common Plastic Waste Into Gasoline and Diesel at Low TemperaturesDaiichi Sankyo and Merck Voluntarily Withdraw US Application for Lung Cancer Drug Ifinatamab Deruxtecan Following FDA DiscussionsScience News: A Century of Independent Scientific Journalism and the Evolution of Public Literacy
YOU MAY HAVE MISSED
Stem Cell & Regenerative Medicine
Dual-Drug Therapy Breakthrough Offers New Hope for Acute Myelogenous Leukemia Patients in Landmark Ludwig Cancer Research Study
Dwi Wanna Sep 29, 2026
Advanced Materials Science
Molten Salt Breakthrough: Oak Ridge Researchers Convert Common Plastic Waste Into Gasoline and Diesel at Low Temperatures
Nila Kartika Wati Sep 29, 2026
Pharmaceutical R&D
Daiichi Sankyo and Merck Voluntarily Withdraw US Application for Lung Cancer Drug Ifinatamab Deruxtecan Following FDA Discussions
Teuku Ryan Sep 29, 2026
Environmental & Analytical Chemistry
Science News: A Century of Independent Scientific Journalism and the Evolution of Public Literacy
Abdurrohim Arsyad Sep 29, 2026

Copyright © 2026 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ